Elucidation of pathological condition of sepsis by using iPS cells for creation of novel therapy
| Project/Area Number |
25861727
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Emergency medicine
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
KASUDA Shogo 奈良県立医科大学, 医学部, 助教 (70434941)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 敗血症 / sphingosine-1-phosphate / 血管内皮細胞 / iPS細胞 / Sphingosine-1-phosphate |
|---|
| Outline of Final Research Achievements |
iPS cells differentiated into hematopoietic embryoid body (EB) in order to establish novel therapy for sepsis. We revealed that EB protected the endothelial integrity by producing Sphingosine-1-phosphate (S1P).
Intravenous injection of EB into sepsis mice significantly restored their survival rates compared to saline-injected mice. Also, onset of lung edema was protected by EB injection. S1P produced from EB exerted protective effects on endothelial integrity of lungs, resulting in inhibition of sepsis progression.
|
Report
(3 results)
Research Products
(1 results)
